abstract |
The present invention provides inhibitors of the huTNFR1 receptor, which are human or humanized antibody constructs that monovalently recognize huTNFR1 through an antigen-binding moiety, characterized by specific CDR sequences; pharmaceutical formulations of said inhibitors; producing said inhibition A method of an agent; and a medical use of the inhibitor. |